Cidara Therapeutics (NASDAQ: CDTX) common stock set to be delisted from Nasdaq

Rhea-AI Filing Summary

Cidara Therapeutics, Inc. is being removed from listing and registration on the Nasdaq Stock Market LLC for its common stock. Nasdaq certifies that it has followed its own rules under 17 CFR 240.12d2-2(b) to strike this class of securities from listing and/or withdraw its registration. The filing also notes that Cidara has complied with the exchange’s rules and the requirements of 17 CFR 240.12d2-2(c) for voluntary withdrawal of the common stock from listing and registration.

Positive

• None.

Negative

• Cidara Therapeutics’ common stock is being removed from listing and registration on Nasdaq under 17 CFR 240.12d2-2, indicating a formal delisting from a national exchange.

Insights

Equity markets and listing standards analyst

Cidara’s common stock is being delisted from Nasdaq under Exchange Act rules.

The notification states that Cidara Therapeutics’ common stock will be removed from listing and registration on the Nasdaq Stock Market. Nasdaq indicates it has met the conditions of 17 CFR 240.12d2-2(b), which govern an exchange’s authority to strike a security from listing when its own rules permit.

The text also states that Cidara has complied with Nasdaq’s rules and 17 CFR 240.12d2-2(c), the provision covering an issuer’s voluntary withdrawal of a class of securities from listing and registration. This combination points to a formal delisting process consistent with federal securities regulations. Actual trading venue and liquidity outcomes beyond this removal are not detailed in the excerpt.

For investors, a move off a national securities exchange typically affects trading visibility and may influence how some institutions can hold or trade the shares. Subsequent disclosures in company communications or future filings would be the place to look for any replacement listing venue or alternative trading arrangements.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-36912

Issuer:	Cidara Therapeutics, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	6310 Nancy Ridge Drive, Suite 101
	San Diego	CALIFORNIA	92121
Telephone number:					(858) 752-6170

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-01-07	By	Tara Petta		Director
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Cidara Therapeutics’ Form 25 filing mean for CDTX?

The Form 25 states that Cidara Therapeutics, Inc. is having its common stock removed from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act.

Which securities of Cidara Therapeutics are affected by this Form 25?

The filing specifies the affected security as Common Stock of Cidara Therapeutics, Inc., which is being struck from listing and/or having its registration withdrawn on Nasdaq.

Who initiated the removal of Cidara Therapeutics’ stock from Nasdaq?

The document states that Nasdaq Stock Market LLC has complied with its rules under 17 CFR 240.12d2-2(b) to strike the class of securities, and that Cidara Therapeutics has complied with exchange rules and 17 CFR 240.12d2-2(c) for voluntary withdrawal.

Is Cidara Therapeutics’ delisting from Nasdaq voluntary or involuntary?

The text cites both 17 CFR 240.12d2-2(b) (exchange action) and 17 CFR 240.12d2-2(c) (issuer voluntary withdrawal), and notes that Cidara has complied with the requirements governing voluntary withdrawal from listing and registration.

Which exchange is Cidara Therapeutics being removed from?

The filing identifies the exchange as the Nasdaq Stock Market LLC, which is the market where Cidara Therapeutics’ common stock has been listed and from which it is being removed.

Who signed the Form 25 for the Cidara Therapeutics delisting?

The notification is signed on behalf of Nasdaq Stock Market LLC by Tara Petta, identified with the title Director.